1.
Evaluating the Clinical and Economic Outcomes Associated with Poor Glycemic Control in People with Type 1 Diabetes in the Netherlands
2.
Once-weekly semaglutide for patients with type 2 diabetes: a cost-effectiveness analysis in the Netherlands